Drug profile · INN
dalbavancin hydrochloride
DALBAVANCIN HYDROCHLORIDE
dalbavancin hydrochloride (DALBAVANCIN HYDROCHLORIDE) is a peptidoglycan inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — dalbavancin hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
dalbavancin hydrochloride (DALBAVANCIN HYDROCHLORIDE) is a peptidoglycan inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Peptidoglycan inhibitor
Primary target: Peptidoglycan
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dalbavancin hydrochloride?
dalbavancin hydrochloride (DALBAVANCIN HYDROCHLORIDE) is a peptidoglycan inhibitor. Associated with Teva Pharma GmbH. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for dalbavancin hydrochloride?
DALBAVANCIN HYDROCHLORIDE is a marketed brand name for dalbavancin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dalbavancin hydrochloride?
dalbavancin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.